PAOG To Build On CBD Business Through Acquisition
2021年10月5日 - 11:42PM
InvestorsHub NewsWire
PAOG To
Build On CBD Business Through Acquisition
Sandusky, OH --
October 5, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc.
(USOTC:
PAOG) today announced the company is actively exploring merger
and acquisition opportunities targeted at expanding the company’s
product line and accelerating revenue
growth.
The company
recently announced initiating production on its first line of CBD
nutraceuticals and being on track to generate its first revenue
this year, in 2021, since entering the CBD market
sector.
PAOG is
developing CBD pharmaceutical and nutraceuticals from its
intellectual property associated with a
patented cannabis extraction method - U.S. Patent
No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING
HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS
PLANT."
The 2020 CBD Nutraceuticals
Market had an
estimated value of $5.2 Billion, and it is expected to reach $16.4
Billion by 2027.
PAOG plans to
distribute its nutraceuticals through North American Cannabis
Holdings, Inc. (USMJ).
PAOG has also entered into a marketing partnership with Puraiton,
Inc. (PURA).
PAOG’s CBD nutraceutical developments stem
from the company’s long-term CBD pharmaceutical initiative built on
a CBD intellectual property acquisition from Nouveau Life
Pharmaceuticals (NOUV).
PAOG’s merger and acquisition objective is
to complement its existing CBD intellectual property while
diversifying its product production opportunity and accelerating
the potential for rapid revenue
growth.
Learn more about
PAOG at www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
過去 株価チャート
から 11 2024 まで 12 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Nouveau Life Pharmaceuticals Inc (PK) (その他OTC): 0 recent articles
その他のNouveau Life Pharmaceuticals Inc (PK)ニュース記事